期刊文献+

多西他赛联合顺铂治疗转移性乳腺癌的临床观察 被引量:5

The clinical observation of combined therapy with docetaxel and cisplatin in treatment of metastatic breast cancer
下载PDF
导出
摘要 目的:观察多西他赛联合顺铂治疗转移性乳腺癌的疗效及不良反应。方法:选择我科2005年6月-2008年6月收治的31例转移性乳腺癌患者,给予多西他赛联合顺铂(TP方案)化疗,21d为1个周期,2周期后评价疗效。有效者给予6周期的化疗。结果:31例患者有效率51.6%,其中CR2例,PR14例。中位疾病进展时间8.6个月,中位生存时间19.2个月。主要不良反应为骨髓抑制及消化道反应和脱发。其中Ⅲ度以上白细胞减少的发生率26.0%。结论:多西他赛联合顺铂治疗转移性乳腺癌的疗效确切,不良反应可以耐受。 Objective:To study the efficacy and side effects of concurrent docetaxel with cisplatin for metastatic breast cancer. Methods: To select 31 metastatic breast cancer patients 17 patients were treated by marcellomycin, ld patients were not treated by marcellomycin previously. All of them were treated with docetaxel and cisplatin combination regimen for two weeks followed by one week rest as one cycle, the clinical effect were evaluated after two cycles. Results: Of all the 31 patients ,2 eases were completely response and 14 cases were partially response, and the total effective rate was 51.6%. The progression of disease time(TFP) was 8.6 months,median survival time was 19.2 months . The main toxicity included the tolerable alimentary tract reaction, bone marrow depression and baldness, 26.0% patients developed degree Ⅲ myelosuppression. Conclusion:The combination of docetaxel and cisplatin treating the metastatic breast cancer patients is effective and with tolerated adverse effect.
出处 《现代肿瘤医学》 CAS 2009年第8期1493-1494,共2页 Journal of Modern Oncology
关键词 多西他赛 顺铂 转移性乳腺癌 化疗 docetaxel cisplatin metastatic breast cancer chemotherapy
  • 相关文献

参考文献6

二级参考文献24

共引文献130

同被引文献54

  • 1陈绍俊,李桂生.多西紫杉醇联合卡培他滨和奥沙利铂治疗28例晚期胃癌[J].肿瘤学杂志,2007,13(2):144-145. 被引量:6
  • 2Beresford M J, Harris AL, Ah-See M, et al. The relationship of the neoangiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer [ J ]. Br J Cancer, 2006,95 ( 12 ) : 16S3.
  • 3Vasey PA, Jayson GC, Gordon A, et al. Phase Ⅲ randomized trial of doetaxel-csrboplatin vemus paclitaxel- carboplatinas first-line chemotherapy for ovarian carcinoma[J].J Natl Cancer Inst,2004 ,96( 22 ) :1682.
  • 4Ferrandina G, Ludovisi M, De Vincenzo R, et al. Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase Ⅱ study[J].Ann Oncol,2007,18(8) :1348.
  • 5Oh DY, Kim TY, Kwon JH, et al. Docetaxel + 5- fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unreseetable gastric cancer[J].Jpn J Clin Oncol,2005,35 (7) :380.
  • 6刘新春,程玉峰,李德爱.实用抗肿瘤药物治疗学[M].北京:人民卫生出版社,2011:745.
  • 7Zielinski C,Beslija S,Mrsic Krmpotic Z,et a1.Gemcitabine,epirubicin,and paclitaxel versus fluorouracil,epirubicin,and cyclophosphamide as first-line chemotherapy in metastatic breast cancer:a Central European Cooperative Oncology Group International,multicenter,prospective,randomized phase Ⅲ trial[J].Clin Oncol,2005,23:1401-1408.
  • 8Cancer Therapy Evaluation Program,Common Terminologycriteria for Adverse Events Version 3.0,DOCT,NCI,NIH.DHHS[2003-3-31]http://ctep.cancer.gov.
  • 9Zeinalzadeh M,Basirat Z,Esmailpour M,et al.Efficacy of letrozole in ovulation induction compared to that of clomiphene citrate in patients with polycystic ovarian syndrome[J].J Reprod Med,2010,55(1-2):36.
  • 10王向明,叶金辉,练英妮,邵剑锋.多西他赛(希存)联合希罗达治疗转移性乳腺癌的临床观察[J].中国肿瘤临床与康复,2007,14(5):457-459. 被引量:3

引证文献5

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部